IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

May 05, 2021
Generic-Drug Makers Knock States' Objection To Sanctions

Generic-drug makers accused of participating in an industrywide price-fixing scheme are urging a Pennsylvania federal court to disregard state enforcers' objections to a special master's recommendation to sanction the California attorney general's office for failing to fulfill discovery obligations in the multidistrict litigation.
April 27, 2021
AGs Warn Against Sanctioning Calif. In Generics Pricing MDL

The attorneys general of Pennsylvania, Oregon and Minnesota urged a Pennsylvania federal judge to reject a special master's recommendation to sanction the California Attorney General's Office for failing to fulfill discovery obligations in multidistrict litigation over inflated medication prices, arguing that it has broad implications.
April 07, 2021
States Too Late To Question Report In MDL, Drugmakers Say

A coalition of generic-drug companies filed an opposition brief on Wednesday blasting a group of state attorneys general for contesting a special master's recommendation in sprawling multidistrict litigation accusing much of the generic-drug industry of price-fixing, arguing that the states' motion is untimely.
April 06, 2021
Calif. AG Says Sanctions Rec. 'Misunderstands' Generics MDL

The California Attorney General's Office said a special master went too far in recommending sanctions against it for not living up to discovery obligations in a multidistrict litigation that accuses much of the generic-drug industry of price-fixing, saying Monday all the material is coming from the defendant drugmakers and third parties.
March 30, 2021
Generics Cos. Argue For Heritage Bellwether In Antitrust MDL

A group of generic-drug makers facing multiple antitrust complaints for allegedly working in concert to inflate medication prices has urged a Pennsylvania federal judge to choose a case against Heritage Pharmaceuticals as the bellwether.
March 23, 2021
Generics MDL Special Master Says Calif. AG Merits Sanctions

A special master on Monday recommended that the California Attorney General's Office be sanctioned for failing to live up to discovery promises in the sprawling multidistrict litigation that accuses much of the generic drug industry of price-fixing, saying the office should be limited to only evidence that was produced on deadline.
March 17, 2021
States Push New Bellwether Generic Drug Price-Fixing Case

If a Pennsylvania federal judge wants to swap out the bellwether case in sprawling litigation that accuses much of the generic drug industry of price-fixing, a coalition of attorneys general want her to choose a different state-brought case than the one she's currently considering as a replacement.
March 02, 2021
Teva, Mylan Back Plan For New Bellwether In Price-Fix MDL

Mylan, Teva and Par Pharmaceuticals are among a group of generic-drug makers that told a Pennsylvania federal judge Monday they're fine with her plan to swap out a bellwether case in multidistrict litigation that accuses most of the generics industry of price-fixing.
February 09, 2021
Teva-Centric Price-Fix Case Likely To Lose Bellwether Status

A Pennsylvania federal judge said Tuesday she was "no longer convinced" that a price-fixing lawsuit centered around Teva from state attorneys general should serve as a bellwether trial for multidistrict litigation accusing most of the generic-drug industry of price-fixing, thanks to related criminal charges against the company.
January 03, 2021
Antitrust Conduct Cases To Watch In 2021

U.S. technology companies are facing a mountain of antitrust litigation heading into 2021, as enforcers push blockbuster monopolization cases against Google and Facebook. Meanwhile, long-running criminal probes in the generic drug and poultry industries are heating up. Here’s a look at the biggest antitrust conduct cases to watch.

← Previous
1
2
3
4
5
6
7
8
9
10
Next →